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Abstract
Objective: To define the role of gastrointestinal (GI) decontamination of the poisoned patient.
Data Sources: A computer-based PubMed/MEDLINE search of the literature on GI decontamination in the
poisoned patient with cross referencing of sources.
Study Selection and Data Extraction: Clinical, animal and in vitro studies were reviewed for clinical relevance to
GI decontamination of the poisoned patient.
Data Synthesis: The literature suggests that previously, widely used, aggressive approaches including the use of
ipecac syrup, gastric lavage, and cathartics are now rarely recommended. Whole bowel irrigation is still often
recommended for slow-release drugs, metals, and patients who “pack” or “stuff” foreign bodies filled with drugs of
abuse, but with little quality data to support it. Activated charcoal (AC), single or multiple doses, was also a
previous mainstay of GI decontamination, but the utility of AC is now recognized to be limited and more time
dependent than previously practiced. These recommendations have resulted in several treatment guidelines that
are mostly based on retrospective analysis, animal studies or small case series, and rarely based on randomized
clinical trials.
Conclusions: The current literature supports limited use of GI decontamination of the poisoned patient.
Introduction
In the United States, the American Association of Poi-
son Control Centers (AAPCC) reported about 2.4 mil-
lion poisoning exposures a year in 2006, while the
Institute of Medicine in 2001 estimated more than 4
million poisoning episodes with 300,000 hospitalizations
and 24,173 poisoning-related deaths [1-3]. This article
will review the current recommendations, guidelines and
data on gastrointestinal (GI) decontamination in the
poisoned patient.
Gastrointestinal decontamination of the poisoned
patient has evolved significantly over the last 2 1/2 dec-
ades from a very invasive to a less aggressive approach.
This less aggressive approach to GI decontamination
followed a series of position statements published jointly
by the American Academy of Clinical Toxicology
(AACT) and the European Association of Poison Cen-
tres and Clinical Toxicologists (EAPCCT) in the late
1990s into the early 2000s [4-9]. Despite the publication
of these guidelines and several outstanding reviews
[10-12], data suggest that few clinicians have read the
guidelines and many have poor knowledge about the
use of GI decontamination [13]. In addition, uniform
advice on this topic has not been demonstrated from
poison information centers [14].
Criteria for selection and assessment of literature
An extensive PubMed/MEDLINE search for gastroin-
testinal decontamination, activated charcoal (AC), multi-
ple dose activated charcoal (MDAC), ipecac, ipecac
syrup, gastric emptying (GE), gastric lavage (GL), whole
bowel irrigation (WBI), body packers, body stuffers and
poisoning treatments was done from about 1980 to pre-
sent. Specific drugs including acetaminophen, anticon-
vulsants, N-acetylcysteine, theophylline, salicylic acid/
aspirin, digoxin, yellow oleander and isoniazid were
searched for relevant studies related to AC and poison-
ing. Human clinical trials with randomized GI deconta-
mination treatments and outcome data were given the
highest priority in the review.
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Gastrointestinal decontamination/ipecac
In the late 1970s and early 1980s, the use of ipecac
syrup to induce vomiting after oral poisoning was wide-
spread both at home and in the hospital [15]. Earlier
work had suggested it was safer than the parenterally
dosed apomorphine [16]. Ipecac contains alkaloids from
the plants cephalis acuminata and cephalis ipecacuanha.
The active compounds of these plants include emetine
and cepheline, which cause emesis by local gastric irrita-
tion and stimulation of the chemotrigger zone of the
brain. The most common side effects from ipecac
include multiple episodes of vomiting persisting longer
than 60 min, aspiration pneumonia, bronchospasm,
Mallory-Weiss tears of the esophagus, bradycardia and
barotrauma to the mediastinum.
In a simulated overdose study of acetaminophen, ten
healthy subjects ingested 3 g of acetaminophen followed
by no intervention, ipecac or 50 g AC-sorbitol solution
at 1 h with acetaminophen levels being repeatedly
drawn [17]. Both treatments significantly (P ≤ 0.05)
reduced serum acetaminophen levels compared to con-
trol, but no differences between ipecac or AC treat-
ments were seen. Using a simulated salicylate model, 12
adult volunteers took 24 81-mg aspirin tablets and were
randomly treated as controls or with ipecac, AC plus
magnesium sulfate or ipecac plus AC plus magnesium
sulfate [18]. Total urinary salicylate excretion found
96.3% ± 7.5% of the salicylate in the control, 70.3% ±
11.8% after ipecac and 56.4%± 12% after AC plus mag-
nesium sulfate. Only eight of ten patients who received
ipecac plus AC plus magnesium sulfate were able to
retain the AC, making analysis of this group impossible.
The use of AC alone significantly reduced the recovered
salicylate compared to both control (P < 0.01) and ipe-
cac groups (P <0.01), while ipecac treatment signifi-
cantly reduced (P < 0.01) recovered salicylate levels
compared to control [18].
In a series of four randomized trials, GE with ipecac
for alert patients or GL for obtunded patients was fol-
lowed by AC and compared to AC alone [19-22]. No
improvement in outcomes was seen when GE
approaches plus AC treated patients were compared to
AC treatment alone. Three out of four of the studies
reported higher complication rates with GE procedures,
with aspiration pneumonia being the most predominant
[19-21]. Aspiration pneumonia was more common after
combined GE and AC treatment than with AC alone
[20,21]. An unblinded trial of children less than 6 years
old who presented with mild to moderate acute oral
ingestions were randomized to ipecac followed by AC
versus AC alone [23]. There was no significant differ-
ence in clinical outcomes reported in the 70 patients
randomized, but it took significantly longer to receive
the AC when ipecac was given (2.6± 0.1 h vs. 0.9± 0.1
h, P < 0.05). As a result, those receiving ipecac spent
significantly longer time in the emergency department
(ED) (4.1± 0.2 h vs. 3.4± 0.2 h, P < 0.05). Home use of
ipecac also has failed to reduce ED use or to improve
outcomes in a cohort comparison [24].
The combined position statement of the AACT and
EAPCCT concluded that there was no evidence from
clinical studies that ipecac improves the outcome of poi-
soned patients and its routine administration in the ED
should be abandoned [4]. This was followed by a guide-
line released by the AAPCC that suggested ipecac
should only be used at home if there would be a delay
of 1 h or more before a patient could get to an ED and
then only if it could be administered within 30-90 min
after the ingestion [25]. The American Academy of
Pediatrics recommended removing all ipecac from the
home setting and that ipecac should not be used routi-
nely as a home treatment for pediatric poisonings [26].
A dramatic reduction in the use of ipecac in the poi-
soned patient has resulted. In 1985, 14.99% (132,947) of
human poison exposures reported to the AAPCC
received ipecac, but by 2009 only 0.02% (658) received
ipecac [27].
Gastrointestinal decontamination/gastric lavage
The use of GL for patients with oral poisons who were
obtunded or with altered mental status was a standard
approach until the 1990s. Matthew et al. [28] in 1966
noted that data from as early as 1942 had questioned
the efficacy of GL, but after studying 259 patients who
had ingested a poison, he concluded that when GL was
performed within 4 h after ingestion, significant recov-
ery of barbiturates in the lavage fluid could still be
demonstrated.
As noted before, various GE procedures were studied
in acute poisoning cases in the five previously men-
tioned studies that also included ipecac treatment arms
[19-23]. Specifically, GL used for obtunded patients in
three of the trials [19,21,22] was compared to AC treat-
ment alone. Two of the studies found no significant
improvement in clinical outcome with GL compared to
AC [21,22]. One study [19] noted that obtunded, poi-
soned patients who had GL plus AC within 1 h of inges-
tion had significantly (P < 0.05) less deterioration
compared to AC treatment alone. The use of GL plus
AC was associated with a significantly (P = 0.0001)
increased incidence of aspiration pneumonia in one
study compared to AC alone in symptomatic patients
(8.5% vs. 0.0%) [21]. In a review of four studies that
evaluated GL versus AC in acetaminophen overdoses,
no strong evidence was found for the routine use of GL
[29].
A study of volunteers who had a 34-French orogastric
tube placed after acetaminophen ingestion reported that
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GL within 1 h resulted in a significant reduction in acet-
aminophen bioavailability [30]. Another study of
patients who presented within 4 h of acetaminophen
ingestion were randomized to no intervention, GL, AC
or treatment with ipecac [31]. A significant reduction in
serum acetaminophen levels was seen with ipecac, GL
or AC treatments compared to no treatment [31]. Use
of AC within 4 h of ingestions resulted in the greatest
decrease in acetaminophen levels, greater than those
seen with both the GL (P = 0.013) and the ipecac syrup
treatment groups (P = 0.027). Despite those acetamino-
phen serum reductions, no clinical outcome differences
between the groups were reported [31]. A review of two
small trials of volunteers with simulated aspirin/non-
steroidal anti-inflammatory drug overdoses found no
advantage to GL over AC alone [32].
In a study of patients with tricyclic antidepressant
overdoses, treatment was randomized to AC, saline GL
followed by AC or AC followed by saline GL followed
by AC [33]. All three approaches had similar clinical
outcomes with no advantage to GL. A systematic review
of controlled trials of GL in acute organophosphorus
pesticide poisoning found no “high-quality” evidence to
support the use of GL in treating these poisonings [34].
One theoretical concern with the use of GL is the
potential of flushing drugs out of the stomach into the
small intestines. A systematic review of this topic failed
to find published data that supported this concern [35].
The major complications with GL include perforation of
the esophagus and stomach, pulmonary aspiration and
aspiration pneumonia. In an observational study of 14
consecutive GLs performed in four hospitals in Sri
Lanka, Eddleston et al. observed five aspirations and two
major cardiac events during the procedure [36]. A
recent study from India of 98 pesticide-poisoned
patients found aspiration pneumonia in 2.2-13.2% of the
patients depending on whether the lavage occurred in
the academic or referral hospital [37]. A drop in arterial
saturations was seen in 13.3%, and laryngospasm, tachy-
cardia, electrolyte imbalance or tube stuck in throat was
each at 2.2% [37]. Although these may be higher com-
plication rates than expected in modern health care
facilities, it draws a warning about the potential risk of
GL [36].
Significant limitations exist in calculating the power
needed to show treatment differences in clinical trials
related to GE and the treatment of actual poisoned
patients. Patients take different combinations of drugs,
different amounts, at different times and have different
co-morbidities, which all confound the potential ability
of a treatment like GE from altering the clinical course.
These limitations must be considered when interpreting
the results of treatments like GE in studies using actual
poisoned patients.
In a review, Bond [38] notes that GL with AC should
be considered for symptomatic patients who present
within 1 h, who have ingested agents that slow gastroin-
testinal motility, who have ingested sustained-release
medication or who have ingested massive/life-threaten-
ing amounts of a medication. This recommendation is
in contrast to the 1997 AACT/EPCCT guidelines, which
state that GL should not be used for routine poisonings,
as there is no certainty that it improves clinical out-
comes. Further, the guidelines suggest GL should only
be considered in a potentially life-threatening ingestion
and then only if it can be undertaken within 60 min of
ingestion [5]. Of the over 2.4 million AAPCC reported
poisonings in 2009, only 6,093 (0.25%) of the total
patients and only 238 (0.02%) of those patients ≤ 5 years
of age underwent GL [27].
Gastrointestinal decontamination/cathartics
Non-absorbable sugars such as sorbitol and salts includ-
ing magnesium citrate and sodium sulfate have been
used as adjuncts to AC to hasten the elimination of the
poison-charcoal complex. One experimental trial
reported reduced systemic absorption of aspirin, but not
pentobarbital, chlorpheniramine or chloroquine when
AC was given with sodium sulfate [39]. Activated char-
coal alone or in combination with sodium sulfate were
thought to be effective, and both approaches reduced
the absorption of drugs compared to sodium sulfate
alone [39]. Using healthy volunteers in a simulation of
an aspirin overdose, AC was more effective than water
alone in reducing salicylate absorption as measured by
the area under the concentration curve (AUC) (428.24±
218.64 μg/ml·h vs. 846.54± 292.95 μg/ml·h, P < 0.01)
[40]. Activated charcoal with sodium sulfate had no
added effect in reducing aspirin absorption and did not
significantly reduce the AUC compared to water alone
(618.61± 324.71 μg/ml·h vs. 846.54± 292.95 μg/ml·h,
NS) [40]. The authors concluded that adding sodium
sulfate to AC did not improve the efficacy of AC.
A survey of EDs in 1991 found that the combination
product of AC plus sorbitol was frequently the only AC
product stocked in EDs [41]. Even when it was not the
only available preparation, 49% of EDs reported giving
repeat doses of AC and sorbitol routinely when the
MDAC approach was used [42]. Cathartic use is asso-
ciated with diarrhea, and when multiple doses of cathar-
tics are given, significant free water loss and dehydration
can occur. Three cases of severe hypernatremia were
reported with magnesium citrate cathartic use in the
management of overdoses [43].
The 1997 AACT/EAPCCT position statement notes
that cathartics alone have no role in the management of
the poisoned patient [6]. Further, the routine use of a
cathartic in combination with AC was not endorsed [6].
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The 2009 AAPCC report found that 22,034 (0.89%) of
calls regarding poisoned patients were treated with cath-
artics, and most were used with AC [27].
Gastrointestinal decontamination/whole bowel irrigation
(WBI)
Many substances are not fully bound by AC. These
include slow-release medications, electrolytes and
metals. In an attempt to reduce GI drug transit time,
polyethylene glycol (PEG) electrolyte solution with rates
of 0.5 to 2.0 l/h have been given to poisoned patients to
reduce transit time of the toxic material, to get the poi-
son beyond the GI areas of drug absorption and even-
tually to be eliminated. The goal of WBI is to remove
the substance from the GI tract prior to it being
absorbed.
Both simulated overdose or nontoxic exposure studies
and clinical overdose cases have questioned the efficacy
of WBI particularly in combination with MDAC
[41,44-47]. In vitro data have demonstrated adsorption
of PEG by AC, which in turn reduced the adsorption of
salicylic acid by AC [48]. These investigators questioned
the use of AC and WBI together in treating overdoses
[48]. No randomized controlled trials have been
reported evaluating the efficacy of WBI.
Using enteric-coated aspirin, ten adult volunteers
received AC combined with sorbitol, water alone (con-
trol) or WBI. Both WBI and the AC with sorbitol signif-
icantly (P < 0.001) reduced absorption as determined by
the salicylic acid AUC. Whole bowel irrigation demon-
strated the greatest reduction in salicylic acid AUC
compared to AC (P < 0.05) and was associated with
fewer adverse effects [49]. In another study, nine healthy
patients received sustained-release preparations of car-
bamazepine, theophylline and verapamil followed 1 h
later by AC, AC with WBI or water (control) [50]. Acti-
vated charcoal reduced the absorption as measured by
the serum AUC by 62%-75% for all three drugs com-
pared to control, but the addition of WBI to the AC
actually significantly (P < 0.01) reduced the efficacy of
the AC with carbamazepine (AC, 62% reduction in AUC
vs. WBI/AC, 41% reduction in AUC). Similarly, the
AUC for theophylline with WBI/AC resulted in less
reduction in AUC compared to AC alone (65% vs. 75%
reduction in AUC, P < 0.001) [50]. In contrast the com-
bination of WBI/AC resulted in a greater reduction of
verapamil absorption (85% reduction in AUC) compared
to AC alone (63% reduction in AUC, P < 0.001) [50]. A
study of anesthetized dogs given sustained-release theo-
phylline and treated with either AC, WBI followed by
AC or AC followed by WBI failed to demonstrate
further reductions in theophylline absorption when WBI
was added to the treatment [51].
The most common complication with WBI is pulmon-
ary aspiration. Contraindications for its use include
compromised airway, hemodynamic instability, seizures,
and the lack of bowel sounds or a suspected or docu-
mented bowel obstruction [52].
Though many of the simulated poison studies have
not demonstrated a benefit of WBI with or without AC,
several case reports note improved outcomes using WBI
for unusual exposures including slow-release medica-
tions such as theophylline, mercuric oxide, lead, stron-
tium ferrite, potassium capsules and even lead bullets
[53-58]. These case reports obviously lack controls or
even historic controls, drawing into question whether
improved outcomes were really demonstrated.
The 1997 AACT/EAPCCT position statement recom-
mended that WBI not be used routinely in the manage-
ment of the poisoned patient. Based only on volunteer
studies and without randomized clinical studies, the
paper recommends that WBI be considered for poten-
tially toxic ingestions of sustained-release or enteric-
coated drugs. Because of the lack of data, WBI remains
a “theoretical” option for iron, lead or zinc poisonings,
or for packets of illicit drugs [59]. A follow-up position
paper in 2004 concluded “no new evidence” existed that
would require a revision of the previous statement on
WBI [60]. It would appear that WBI has a very limited
role in the treatment of the poisoned patient. Only
2,108 (0.09%) of total patients and 130 (0.01%) of those
patients ≤ 5 years old received WBI out of the more
than 2.4 million total poisoned patients reported in
2009 to the AAPCC [27].
Gastrointestinal decontamination/special consideration/
body packers/body stuffers
Body packers or “mules” are people who smuggle illicit
drugs (mostly cocaine or opium/heroin) concealed in
the mouth, rectum, vagina, ear, foreskin or gastrointest-
inal tract. The drugs are often packaged in capsules,
condoms, balloons or plastic bags. Drugs in most of the
anatomical body cavities or orifices can be manually
removed except when they have been ingested. Once in
the GI tract, decontamination or removal can be chal-
lenging, and perforations of the drug container can be
fatal. A variation of the concept of the body packer is
the “body stuffer” who ingests drugs in aluminum foil or
plastic bags often hastily to avoid police seizure of the
drug/evidence. A further variation of “body stuffing” is
“parachuting” in which the illicit drug (often metham-
phetamine or cocaine) is swallowed in a plastic baggie
that has been punctured multiple times to allow a slow-
release of the drug [61]. Adults are usually involved in
cases of body packing/stuffing, but disturbing reports of
pediatric body packers have surfaced [62].
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A recent review of approaches to GI decontamination
in these patients noted no randomized clinical trials
exist, leaving only case studies and series available to
guide our approach [63]. One European series from
Paris and Frankfurt included approximately 4,660 body
packers. The vast majority of the body packers were
asymptomatic. About 1.4% of the body packers (n = 64)
had life-threatening symptoms of cocaine overdose after
rupture or leakage of a container. Forty-four of these
body packers died before surgical intervention to
remove the packets could be performed, while 20 under-
went emergency laparotomy for the removal of the con-
tainers and all of these patients survived [64]. Urgent
surgery is routinely recommended for symptomatic
patients with obstruction, bowel perforation or evidence
of drug packet rupture [63-66].
Although surgery has been considered definitive in
these cases, a report noted two cases where, despite
careful surgical inspection and palpation of the entire
GI tract, additional drug packets were identified after
surgery by CT scans [67]. Plain abdominal radiographs
are reported to have sensitivity for finding drug packets
of between 85-90% [68-70]. Contrast-enhanced abdom-
inal radiography has been reported to increase sensitivity
to 96% [68,71]. Although no large studies have been
done with abdominal CT scanning, its use has been
widely reported with CT window manipulation, identify-
ing packets that would not have been seen on routine
windows [68,72]. Unfortunately, at least two cases of
drug packets missed by CT scanning have been reported
[67,73].
With little data, conservative non-surgical measures
are routinely used in the majority of patients who are
asymptomatic. These approaches include endoscopy for
packets thought to be retained in the stomach, light
solid diets, oral fluids, AC and most commonly WBI to
clear the GI tract of the drug packets [68]. Oil-based
laxatives have been recommended in the past, but are
now discouraged because of their potential effect on
latex products used to package some drugs [68,74]. The
packets can often be collected after sorting through
stool in a way that preserves them as evidence
[61,75-77]. Although not formally tested, the value of a
systematic surgical protocol for treating body packers
that defines conservative therapy, monitoring
approaches, as well as when to use surgery has been
emphasized [78,79].
Sodium polystyrene sulfonate
The use of sodium polystyrene sulfonate (SPS) has been
recommended in the treatment of lithium overdoses to
prevent further absorption and potentially increase
lithium elimination [80]. The use of SPS for the treat-
ment of hyperkalemia has been clinically widespread
since its approval by the FDA in 1958. Recently, the effi-
cacy and safety of SPS for hyperkalemia have been ques-
tioned [81].
In vitro binding of lithium to SPS has been demon-
strated [82]. Mice studies have shown significant reduc-
tion in lithium levels after oral lithium is followed by
SPS. These reductions have been shown after multiple
doses of SPS and with delays up to 90 min after the oral
dosing of lithium, while treatment with AC has shown
no effect [83-86]. Human subjects exposed to 900 mg
lithium were treated 30 min later with 0, 20 or 40 g of
SPS. Reduced absorption and increased clearance of
lithium were demonstrated with SPS [87]. Two addi-
tional human volunteer studies have confirmed reduced
lithium serum AUC, lower peak levels and delayed time
to peak lithium levels when SPS is given after oral
lithium [88,89]. A retrospective cohort study of patients
with lithium toxicity treated with oral SPS suggested
more than a 50% reduction in lithium serum half-life.
No clinical outcome improvement was reported. Consti-
pation and mild hypokalemia were noted as side effects
of treatment in this study [90].
Hypokalemia is an expected complication of the use of
SPS for lithium overdose, but more troubling are reports
suggesting GI necrosis in uremic patients treated with
SPS [91,92]. The use of sorbitol to prevent fecal impac-
tion and to increase GI motility as an osmotic cathartic
with the SPS powder or as a pre-mixed product has
been suggested to be related to the development of GI
necrosis [81]. Cases of calcium polystyrene sulfonate
without sorbitol-associated GI necrosis exist and bring
into question the importance of sorbitol to the mechan-
ism [93,94]. The incidence of this severe side effect is
not currently known, and to date no cases of GI necro-
sis have been reported as a result of using SPS for the
treatment of lithium-overdosed patients.
Gastrointestinal decontamination/activated charcoal
A dramatic early demonstration of AC occurred when
Tovery, before the 1831 French Academy, took a lethal
dose of strychnine mixed with charcoal. He suffered no
ill effects [10,95,96]. Activated charcoal is a highly
adsorbent material produced by grinding carbon mate-
rial into a fine powder, superheating the carbon source
to very high temperatures, followed by injecting or “acti-
vating” the charcoal with steam to maximize the surface
area. By the 1980s, AC was generally recognized as a
major treatment for most orally poisoned patients [95].
In addition to preventing drug absorption, AC can dis-
rupt drug recycling in an enterohepatic loop and results
in “drug back diffusion” out of the body into the GI
tract. This “gut dialysis,” where drugs move from sys-
temic body compartments to the GI tract, explains how
drugs given intravenously can have increased
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elimination with oral AC. Many trials have documented
increased clearance with oral AC in both human and
animal models after intravenous (IV) phenobarbital,
phenytoin, digoxin, acetaminophen and theophylline
(Table 1). These proposed AC mechanisms go beyond
traditional GI decontamination and actually invoke a
process that increases elimination. Multiple human and
animal studies have suggested that MDAC is potentially
an important treatment approach for many toxins
including some IV poisonings, slow release compounds,
pill bezoars or massive poisonings. In the early 2000s,
some review articles were still supportive of the use of
AC and MDAC (usually without GE), but others began
to question this practice [38,97]. Table 1 offers in-depth
examples of the type of data on AC and MDAC focus-
ing on aspirin, acetaminophen, N-acetylcysteine, antic-
onvulsants, yellow oleander, isoniazid and theophylline
as examples. This table gives the reader details on the
extent and limitations of the clinical and animal data
supporting the use of AC. A meta-analysis that included
64 controlled trials using AC in a variety of drug expo-
sures in healthy volunteers found that AC was most
effective when given within 1 h of the ingestion, but sig-
nificant reductions in drug levels could still be seen
even if given as long as 4 h after drug intake [98].
Reduction in drug absorption also was significantly cor-
related with the AC/drug ratio (P = 0.02). Significant
reductions in drug absorption at an AC to drug ratio of
10:1 were demonstrated, and little further reduction
beyond the 100:1 ratio could be found. It was noted that
drugs with a large volume of distributions demonstrated
greater reductions in absorption with AC [98]. In vitro
and in vivo studies have suggested that an AC to drug
ratio of at least 10:1 for aspirin and acetaminophen should
be obtained to insure maximal efficacy [99]. This recom-
mendation on the AC to drug ratio is consistent with the
findings of the above meta-analysis and has been general-
ized to all drugs with little additional clinical evidence [99].
Trials in actual poisoned patients with single dose AC
or MDAC have shown mixed results. A randomized
trial of ten patients who overdosed on phenobarbital
reported a profound reduction in serum phenobarbital
half-life, but no change in time on mechanical ventila-
tion or the time in the hospital between those receiving
a single dose of AC or MDAC [100]. In contrast, 12
patients with confirmed carbamazepine poisonings were
randomized to receive MDAC or a single dose of AC
[101]. Though peak carbamazepine levels were similar,
the duration of coma was significantly decreased (P =
0.02) as were the hours on mechanical ventilation (P =
0.001) and the length of hospital stay (P = 0.00001) with
MDAC. The serum half-life of carbamazepine was also
significantly (P = 0.004) reduced by more than 50% with
MDAC compared to a single dose of AC.
Merigian and Blaho [102] reported a prospective, ran-
domized, controlled trial of AC compared to control (no
treatment) after oral drug overdoses in patients who
were able to take oral AC. Specific exposures were
excluded, including ingestions of > 140 mg/kg acetami-
nophen, crack cocaine, mushrooms, volatiles, caustics,
heavy metals, lithium and iron [102]. No GE was per-
formed. Almost 1,500 patients were entered into the
study and no difference in outcome parameters was
seen between the two groups. In contrast, de Silva [103],
randomized 401 patients who had ingested yellow olean-
der to MDAC or a single dose of AC. There were fewer
deaths (2.5% vs. 8%, P = 0.025) for those treated with
MDAC compared to a single dose of AC in this study.
In a larger randomized trial that included 4,629 over-
dosed patients, Eddleston reported that there were no
differences in mortality between control, single-dose AC
and MDAC treatment in patients overdosed on various
toxins (51% pesticides and 36% yellow oleander) [104].
A randomized trial of AC compared to control in 327
patients presenting with oral overdoses reported no sig-
nificant reduction in hospital length stay or other
patient outcomes with AC [105].
Compliance has been variable with AC even when
ordered. In the previously mentioned large randomized
controlled trials of control, AC and MDAC [104], a sin-
gle dose of AC was only given 83% of the time, and
only 66% of five doses of MDAC were actually given
[106]. The major reasons for not receiving the AC doses
were patient refusal and active vomiting. A descriptive
study in pediatric poisonings found only 55% of children
were given AC within 1 h of presentation to ED, and
only 7.8% actually got their AC within 1 h of their poi-
soning because of delays in arriving to and delays within
the ED [107]. Karim et al. [108] found that the median
time to arrival after overdose was 136 min, and only 15
out of 63 patients received AC within 1 h of poisoning.
A study in rural Australia reported the time from inges-
tion to ambulance arrival averaged 1 h 23 min, and the
time to hospital averaged 2 h and 15 min [109]. They
concluded that poisonings with long transport times
would have to get AC in the ambulance if they were to
have any chance of receiving AC within 1 h.
Many metals and electrolytes do not bind to AC, such
as iron, lead, potassium and lithium [110]. The lack of
significant binding of these agents to AC eliminates its
potential usefulness in treating potassium, lithium, iron,
lead and other heavy metal exposures.
Although AC is generally well tolerated, a number of
complications have been reported with its use (Table 2).
Many of these complications have been reported as case
reports, and some are associated with MDAC, often as a
result of the cathartic in the combined product. In a
study of 575 poisoned patients treated with AC, adverse
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Table 1 Studies and reports evaluating the effects of activated charcoal on selected drugs
Type
report
Subjects Variables Drug (oral unless
noted)
Conclusion/reference
R, NB,
CCS
HV C, AC, VT Acetaminophen AC at 15, 30 and 120 min reduced acetaminophen urinary recovery
by 48, 44, and 33% [127]
NR, OB,
NB
HPP AC + NAC, NAC Acetaminophen ↓ In serum transaminases and prothrombin times with AC + NAC
compared to NAC alone [128]
NR, OB,
NB
HPP AC + NAC, NAC Acetaminophen ↓ In serum transaminase, major adverse effects and death with AC
and NAC [129]
R, CCS,
NB
HV C, AC-after 1 h, AC-after 2 h,
CL + AC-after 1 h
Acetaminophen All significantly reduced acetaminophen AUC. The AUC was
significantly more reduced when AC given at 1 h compared to 2 h,
and GL did not add to AC alone [130]
R, NB HPP GL, AC, Ip, C Acetaminophen Greatest ↓ in acetaminophen level with AC, then Ip, then GL
compared to C. No clinical differences reported [31]
NR,
Retro,
Ob, NB
HPP GL + AC, AC, C Acetaminophen AC reduced risk for toxic acetaminophen concentrations, GL did not
further reduce risk [131]
R, CCS,
NB
HV NAC, AC + NAC NAC No significant differences in peak NAC levels with AC [132]
NR, NB,
CCS
HV NAC, AC + NAC NAC A 3% reduction in NAC AUC and a 29% reduction in peak NAC
levels with AC [133]
[ HV AC, C Acetaminophen The acetaminophen AUC was 58.9% with AC compared to C
(P = 0.01) [134]
Ob, NB HPP NAC, NAC + AC Acetaminophen The addition of AC significantly (P < 0.05) reduced the T 1/2 and
increased the body clearance of acetaminophen [135]
B, R,
CCS
HV C, AC1, AC2 (variable types of
AC)
Acetaminophen Both types of AC reduced AUC for acetaminophen and peak levels
of acetaminophen [136]
R, CCS,
NB
HV C, AC, AC+ IM atropine Acetaminophen AC significantly reduced AUC for acetaminophen by 20% alone and
by 47% in the presence of atropine [137]
CCS, R,
NB
Pigs C, MDAC (variable times) IV-acetaminophen,
digoxin, theophylline,
valproic acid
Significantly enhanced elimination (P < 0.01) for acetaminophen,
theophylline and digoxin with MDAC, but no increased elimination
with valproic acid [138]
R, CSS,
NB
HV C, AC (variable time after
ingestion)
Acetaminophen +
oxycodone
Compared to control, acetaminophen AUC reduced by 43% 1 h (P <
0.0001), 22% 2 h (P = 0.02) and 15% 3 h (P = 0.26) with AC [139]
R, CCS,
NB
HV C, AC (variable time after
ingestion)
Acetaminophen Compared to control, acetaminophen AUC reduced by 56% 1 h (P <
0.002), 22% 2 h (P < 0.03) and 8% 4 h (NS) with AC [140]
R, CSS,
NB
HV C, AC Sodium amino-salicylic
acid
(1 and 2 g - C,
1 and 2 g - AC,
10 and 20 g - AC
AC was given immediately after salicylic acid. Increasing the dose of
salicylic acid reduced the antidotal efficacy of AC and lead to
increasing salicylic acid AUC. The salicylic acid AUC increased by
more than 4 fold when salicylic acid 10 g dose went to 20 g dose
with AC dose held constant [141]
R, CSS,
NB
HV AC (3 variable doses) Acetaminophen A 59% increase (P < 0.001) acetaminophen AUC was seen between
50 g AC and 5 g AC both given 1 h after drug [99]
R, CCS,
NB
HV C, Ip, GL, AC after 1 h Aspirin Equal reduction in absorption of aspirin as measured by recovered
urine salicylate [142]
R, CCS,
NB
HV C, AC, MDAC (1, 2 or 3 doses
separated by 4 h)
Aspirin All 3 AC doses associated with significant (P ≤ 0.01) reduction in
urinary salicylate recovery. 3 doses of AC resulted in significantly (P <
0.01) greater recovery of salicylate than 1 or 2 AC doses [143]
R, CCS,
NB
HV C, AC Aspirin MDAC associated with a significant (P ≤ 0.01) 9% reduction in serum
salicylate AUC and a significant (P ≤ 0.05) 18% reduction in urinary
excretion. Considered “clinically modest” effect of “questionable
valve” [144]
R, CCS,
NB
HV C, Ip, AC, Ip + AC Aspirin Urinary salicylate recovery was 96.3 ± 7.5% in control, 70.2 ± 12.1%
Ip, 56.5 ± 12.5% AC, 72.7 ± 14.1%, Ip + AC. There was a significantly
greater (P < 0.05) reduction with AC compared to Ip [18]
R, CCS,
NB
HV C, AC (1 h after ingestion) Aspirin, digoxin,
phenytoin
AC reduced the AUC of digoxin (98%), phenytoin (90%) and aspirin
(70) [145]
CCS, NB Canines C, MDAC IV-theophylline at 2
different doses
Nasogastric tube in duodenum, AC resulted in 22-47% decrease in
theophylline AUC [146]
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events occurred in 41 cases (7.1%) with nausea/vomiting
found in 36, bronchoaspiration in 6 and pneumonia in 2
[111]. Spontaneous vomiting before AC, pre-hospital
AC administration, repeated doses of AC and the need
for specific clinical measures to treat intoxicated
patients (e.g., intubation) were all associated with a sig-
nificantly increased risk for an adverse event. A retro-
spective study in which 878 poisoned patients were
treated with MDAC found that 5 (0.6%, 95% CI 0.1-
1.1%) patients had clinically significant aspiration and
none had GI obstruction [112]. No patients died. Mild
hypernatremia (> 145 mEq/l) was seen in 53 patients
(6.0%, 95% CI, 4.4-7.6%), with 5 of these patients having
sodium levels greater than 155 meg/l. Hypermagnesemia
(> 2.5 mg/dl) was seen in 27 patients (3.1%, 95% CI,
2.0-4.2%), and 3 patients had peak values greater than
Table 1 Studies and reports evaluating the effects of activated charcoal on selected drugs (Continued)
R, NB Rats C, AC, MDAC IV-theophylline and
phenobarbital
MDAC significantly decreased theophylline and phenobarbital serum
T 1/2 and AUC while AC had only slight decrease. Thought to be
“adsorption” of exsorbed theophylline and phenobarbital [147]
R, CCS,
NB
HV C, MDAC various doses,
variable intervals for total
dose 150 g AC
IV-theophylline The AUC of theophylline significantly (P < 0.05) reduced near equally
by three schedules of MDAC [148]
R, NB Rats C, MDAC IV-theophylline multiple
doses tested
The theophylline AUC and T 1/2 was reduced by 50% and 52%
respectively by MDAC [149]
NB HPP MDAC Phenytoin/phenobarbital Apparent decreased T 1/2 for phenytoin and phenobarbital only
after MDAC started [150]
NB HPP MDAC Phenobarbital Apparent decreased T 1/2 for phenobarbital with MDAC [151]
R, NB HPP MDAC, AC Phenobarbital In the 5 patients treated with MDAC, the T 1/2 was 36 ± 13 h for
phenobarbital, significantly shorter than T 1/2
after single dose AC in 5 patients. No difference in length of time on
mechanical ventilation or time in hospital [100]
NB HPP MDAC Phenobarbital Apparent decrease in T 1/2 phenobarbital with MDAC [152]
R, CSS,
NB
HV C, MDAC, 24 h of urinary
alkalinization
IV-phenobarbital The T 1/2 of phenobarbital was 148 h, 47 h and 19 h during the
control, alkalinization and MDAC phases, respectively. All statistically
significantly different from each other [153]
R, CSS,
NB
HV C, MDAC IV-phenobarbital MDAC deceased phenobarbital T 1/2 from 110 ± 8 to 45 ± 6 h
(P < 0.01) [154]
NB HPP MDAC Phenytoin Apparent decrease in T 1/2 phenytoin with MDAC [155]
NB HPP MDAC Phenytoin Apparent decrease in T 1/2 phenytoin with MDAC [156]
R, CSS,
NB
HV C, MDAC IV-phenytoin MDAC decreased T 1/2 phenytoin from 44.5 to 72.3 h [157]
R, NB HPP AC, MDAC Carbamazepine MDAC associated with reduced T 1/2 carbamazepine 12.56 ± 3.5 vs.
27.88 ± 7.36 h (P = 0.0004) compared to single dose AC. MDAC also
associated with statistically significant reduced coma, mechanical
ventilation and length of hospital stay [101]
NB HPP MDAC Carbamazepine Apparent decrease in T 1/2 carbamazepine with MDAC [158]
NB HPP MDAC, WBI Carbamazepine Rebound in carbamazepine serum levels despite MDAC [45]
NB HPP MDAC Valproic acid Apparent decrease in T 1/2 valproic acid with MDAC [159]
R, NB HPP C, AC, MDAC Pesticides, yellow
oleander, medicines or
unknown
No difference in rates of mortality between C (6.8%), AC (7.1%) and
MDAC (6.3%). Odds ratio 0.96 (95% (F 0.70-1.33) between C and
MDAC [104]
R, NB HPP C, MDAC Yellow oleander MDAC significantly (P = 0.025) reduced mortality from 8% (control)
to 2.5% (MDAC). Significant reduction in ICU, digoxin FAB fragments
treatment, cardiac pacing, life-threatening arrhythmias, doses of
atropine and time in hospital with more [103]
R, CSS,
NB
HV C, AC Isoniazid AC reduced isoniazid absorption [160]
R, NB Rabbits C, AC Isoniazid AC reduced T 1/2 of isoniazid [161]
R, CSS,
NB
HV C, AC Isoniazid AC 1 h after isoniazid reduced the isoniazid AUC [162]
↑ = increased; ↓ = decreased; AC = activated charcoal; AUC = area under serum curve; B = blinded; C = control; CCS = crossover controlled study; GL = gastric
lavage; HPP = human poisoned patients; HV = human volunteers; IM = intramuscular; Ip = ipecac; IV = intravenous; LiCl = lithium chloride; MC = multiple center;
MDAC = multiple dose AC; NAC = n-acetylcysteine; NB = non-blinded; NC = no change; NR = non-randomized; ob = observational study; R = randomized; Retro
= retrospective; SPS = sodium polystyrene sulfonate; SR = sustained release; T 1/2 = serum half-life; VT = variable time
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3.75 mg/dl. These electrolyte abnormalities were usually
associated with cathartic use, but not exclusively. One
patient had a corneal abrasion that resolved without
complication and was associated with AC getting into
their eyes [112].
In evaluating 50 intubated patients with evidence of
new pulmonary infiltrates on chest X-ray within the first
48 h of hospitalization after AC treatment, only 2 (4%)
had initial negative radiographs and then developed a
new infiltrate after AC. This suggests an infrequent
association of AC to aspiration pneumonia [113]. Severe
cases of pulmonary aspiration of AC resulting in pro-
longed respiratory failure, death, empyema and bronch-
iolitis obliterans have been reported, but these are
isolated case reports [114-117].
The risk factors for emesis after AC in poisoned
patients were found to be prior vomiting before AC and
the use of a nasogastric tube for AC administration. In a
study of 275 children, 56 (20.4%) had vomiting after
administration of AC [118]. Case reports of charcoal
bezoars or inspissated charcoal being associated with
small bowel obstruction exist after treatment with AC,
but these events are also likely rare [119-122]. Acute
appendicitis, charcoal stercolith associated with intest-
inal perforation and charcoal peritoneum has all been
reported with AC treatment [123-126].
The last major practical issue in the decision to use
charcoal for decontamination of a poisoned patient
revolves around time of ingestion. The AACT/EAPCCT
1997 guidelines recommend that single dose AC should
not be routinely administered to poisoned patients and
suggest its effectiveness decreases with time after inges-
tion [7]. If charcoal is to be administered, the greatest
benefit is seen within 1 h after ingestion of poison. There
is no convincing clinical evidence that AC improves clini-
cal outcome [7]. These 1997 recommendations were reaf-
firmed in 2005 with the observation that “no new
evidence” was found to suggest a revision in the
guidelines was needed [8]. When considering MDAC, the
position paper from AACT/EAPCCT suggests that
MDAC should only be considered in patients with pro-
tected or intact airways. MDAC should not be used with
repeat doses of cathartics, and it should only be consid-
ered if a patient has ingested a life-threatening amount of
carbamazepine, dapsone, phenobarbital, quinine or theo-
phylline [9]. In 1995, 7.7% of all poisoned patients and
3.56% of all those patients ≤ 5 years old recorded by the
AAPCC were treated with AC, but by 2009 the percen-
tage had decreased to 3.4% of all poisoned patients and
only 1.48% of patients ≤ 5 years old [27].
Conclusion
Gastrointestinal decontamination with ipecac, GL, AC
and cathartics are now used less often in the hospital
setting in the poisoned patient. Whole bowel irrigation
for the ingestion of slow-release medications and
asymptomatic foreign body drug containers (body
packers/stuffers) is recommended with little quality
clinical data. Current recommendations for the use of
AC and MDAC are limited in the treatment of the
poisoned patient. The use of AC appears to be most
efficacious when given within an hour of ingestion.
The use of SPS as a binder of lithium is based on lim-
ited data. The current recommendations for GI decon-
tamination of the poisoned patient are based on a few
clinical trials, small case series, retrospective analysis
and animal data. The previous aggressive approach to
GI decontamination is increasingly being replaced by
less emphasis on active GI decontamination and more
emphasis on supportive care.
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Table 2 Complications and Adverse Reactions to
Activated Charcoal
Bronchiolitis obliteran after charcoal aspiration and Bronchopulmonary
aspiration
Corneal abrasion
Fluid and electrolyte abnormalities¹
Hypernatremia
Hypermagnesemia
Gastrointestinal tract perforation/charcoal peritonitis
Nausea/vomiting
Pneumonia
Pneumothorax/charcoal-containing empyema
Small bowel obstruction with/without bezoar
1 = When AC given with a cathartic
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